Home    Back

Galactose    (DrugBank: Galactose)

2 diseases
IDDisease name (Link within this page)Number of trials
171Wilson disease1
222Primary nephrotic syndrome4

171. Wilson disease    [ 50 clinical trials,   59 drugs,   (DrugBank: 17 drugs),   3 drug target genes,   28 drug target pathways]
Searched query = "Wilson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 50 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02702765
(ClinicalTrials.gov)		February 201626/2/2016sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and FibrosisMacrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and FibrosisWilsons DiseaseProcedure: Fibroscan;Procedure: Ultrasound;Drug: Galactose;Procedure: Liver biopsy;Procedure: Functional hepatic nitrogen clearanceUniversity of AarhusAarhus University HospitalActive, not recruiting18 Years100 YearsAll33N/ADenmark

222. Primary nephrotic syndrome    [ 234 clinical trials,   241 drugs,   (DrugBank: 78 drugs),   59 drug target genes,   185 drug target pathways]
Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 234 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01113385
(ClinicalTrials.gov)		October 200928/4/2010Oral Galactose in Children With Steroid Resistant Nephrotic SyndromeEffect of Oral Galactose on the Level of Focal Sclerosis Permeability Factor and Proteinuria in Children With Steroid Resistant Nephrotic Syndrome: A Pilot StudyFocal Segmental Glomerulosclerosis;Steroid Resistant Nephrotic SyndromeDrug: D-GalactoseChildren's Research InstituteNational Kidney FoundationCompleted2 Years21 YearsAll7N/AUnited States
2NCT00816478
(ClinicalTrials.gov)		December 200831/12/2008Effect of Oral Galactose on Focal Segmental Glomerulosclerosis (FSGS) Permeability FactorEffect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)Focal Segmental GlomerulosclerosisDrug: GalactoseNorth Shore Long Island Jewish Health SystemNULLTerminated2 Years60 YearsBoth15Phase 1United States
3NCT00816504
(ClinicalTrials.gov)		December 200831/12/2008Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5Effect of Galactose on Permeability Factor in Patients With Focal Segmental Glomerulosclerosis (FSGS)and Chronic Kidney Disease Stage 5Focal Segmental GlomerulosclerosisDrug: GalactoseNorth Shore Long Island Jewish Health SystemMedical College of WisconsinWithdrawn2 Years60 YearsBoth0Phase 1United States
4NCT00814255
(ClinicalTrials.gov)		December 200822/12/2008Novel Therapies for Resistant FSGS (FONTII): Phase II Clinical TrialNovel Therapies for Resistant Focal Segmental GlomerulosclerosisFocal Segmental GlomerulosclerosisDrug: Adalimumab;Drug: Lisinopril, losartan, and atorvastatin;Drug: galactoseNew York University School of MedicineUniversity of Michigan;The Cleveland Clinic;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed1 Year65 YearsAll32Phase 2United States;Canada

Back to top